Antibodies News and Research

RSS

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

UK makes £5.64M investment in most advanced crystallography technology

The UK's structural biology community will have access to the most advanced crystallography technology in the world thanks to a - £5.64M investment from UK research funders.

3 Jun 2014

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

TSRI scientists receive more than $13M to design effective HIV vaccine

A team led by scientists at The Scripps Research Institute (TSRI) has received a grant of more than $13 million from the National Institute of Allergy and Infectious Disease of the National Institutes of Health to study antibodies to the human immunodeficiency virus (HIV)—which will play an essential role in the creation of any effective vaccine against HIV.

30 May 2014

Perelman School wins $10M renewal to study oldest part of human immune system

The National Institute of Allergy and Infectious Diseases has awarded the Perelman School of Medicine at the University of Pennsylvania a five-year, $10 million renewal of a program project to study the oldest part of the human immune system called the complement system, or simply "complement."

30 May 2014

New approach could lead to more effective HIV vaccine

Using a genetically modified form of the HIV virus, a team of University of Nebraska-Lincoln scientists has developed a promising new approach that could someday lead to a more effective HIV vaccine.

30 May 2014

TSRI scientists receive $13M grant to create effective vaccine against HIV

A team led by scientists at The Scripps Research Institute (TSRI) has received a grant of more than $13 million from the National Institute of Allergy and Infectious Disease of the National Institutes of Health to study antibodies to the human immunodeficiency virus (HIV)-which will play an essential role in the creation of any effective vaccine against HIV.

30 May 2014

Polyplus-transfection introduces FectoPRO transfection reagent

Polyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO, the latest optimised transfection reagent in their product portfolio. FectoPRO has been designed for high yields in medium and large-scale production of proteins and antibodies in mammalian cells.

28 May 2014

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies.

28 May 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency).

27 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

International study provides hope to patients with advanced prostate cancer

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

26 May 2014

Antibodies News and Research

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

UK makes £5.64M investment in most advanced crystallography technology

AMRI agrees to acquire OsoBio for $110 million

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

TSRI scientists receive more than $13M to design effective HIV vaccine

Perelman School wins $10M renewal to study oldest part of human immune system

New approach could lead to more effective HIV vaccine

TSRI scientists receive $13M grant to create effective vaccine against HIV

Polyplus-transfection introduces FectoPRO transfection reagent

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Alligator Bioscience acquires rights to drug development candidate ADC-1013

International study provides hope to patients with advanced prostate cancer

Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

Researchers uncover potential vaccine that can stop malaria parasites from multiplying

EKF affirms that novel sTNFR1/2 biomarkers can help predict end-stage renal disease

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo